Enterprise Data Management

Drug pipelines rise or fall on decisions made with imperfect information, yet the signal hidden in clinical registries, regulatory filings, and conference disclosures has remained stubbornly hard to use at scale. That friction has distorted portfolio choices, delayed course corrections, and

Boardrooms demanded explainable AI long before chatbots charmed end users, and the gap between friendly prose and audited numbers left most pilots stranded in “demo limbo” where no one could sign off the results with confidence. Alteryx’s AI Insights Agent set out to close that gap by wiring Gemini

High‑end GPUs remained scarce, queue times stretched from hours to days, and model teams learned the hard way that single‑cloud loyalty often delayed launches more than it protected them from complexity. The case for cross‑cloud was not philosophical; it was practical—get access to capacity,

Two teams ask an AI agent for last quarter’s net revenue retention, receive two different numbers, and both results arrive stamped with confident explanations that sound right but do not agree. That is the moment dashboards stop being helpful, workflows stall, and trust in automation cracks—because

Stockswhipsawed, roadmapswerepaused, and designleadersfieldedpanickedpings as Claude Design’s preview ignited the market while leaving practitioners asking what actual work it could own. This roundup gathers perspectives from analysts, agency principals, enterprise buyers, and system integrators to

Boardrooms kept asking for proof that AI agents could manage messy, real-world work instead of chat-script parlor tricks, and the answer arrived with a staged but telling trial: a multi-agent system planning a full marathon through the chaos of Las Vegas while showcasing the entire lifecycle of